Article
Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project.
ESMO open - 1 May 2026
Sánchez-Bayona R, de Nicolás-Hernández J, Saura C, Gion M, Cejalvo J M, Llabrés E, Cortés J, Falcón A, Pernas S, López de Sa A, Vidal M, Hinojo C, Curiel T, Cruz J, Martínez V, Cantos B, Echarri M J, Gallegos I, Bueno C, Vargas A M, Escrivá-de-Romaní S, Fullana B, Cobos M A, Arenas A, Joval-Ramentol L, Ortiz P, Pascual T, Valdivia C, Villacampa G, Ciruelos E, Rodriguez-Antona C
Abstract excerpt
BACKGROUND: Although trastuzumab-deruxtecan (T-DXd) has demonstrated significant efficacy in advanced breast cancer, treatment discontinuation due to adverse events occurs in ∼20% of patients. Pharmacogenetic variants in uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) increase the toxicity risk for other antibody-drug conjugates using topoisomerase I inhibitors, but they remain unexplored for T-DXd....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.